Hematología y Hemoterapia

Resultados: 405
Tipo Título / Nombre Autor(es) Año
Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse Alegre A, Gironella M, Bergua JM, González E, Esacalante F, Soler A, et al 2014
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, et al 2014
Safety of a new high purity factor X concentrate in the management of hereditary factor X deficiency Norton M, Mitchell WB, Álvarez MT, Austin S, Auerswald G, Bermejo N, et al 2014
Efficacy and safety of a new high purity factor X concentrate in the treatment of severe or moderate factor X deficiency Kavalñ K, Austin S, Álvarez MT, Auerswald G, Bermejo N, Mitchell W [et.al], et al 2014
Pharmacokinetics of a new high purity factor X concentrate in subjects with severe or moderate factor X deficiency Austin S, Álvarez MT, Auerswald G, Bermejo N, Kavakli K, Mitchell W, et al 2014
Relationship Between Extracellular and Intracelular Calcium Mobilization and Platelet Granule Secretion Bermejo N, Berna Erro AR, Redondo Liberal PC, Rosado Dionisio JA, López Nieto E, Salido Ruíz GM, et al 2014
Different Clinical Manifestation of Dysfibrinogenemias Associated to the Mutation Arg275 In Exon 8 of FGG Gene Mesa E, Vila V, Gómez N, Leyva R, Haya S, Cid AR, et al 2014
How we should treat the patients with cryptogenic ischemic stroke or transient ischemic attacks and antiphospholipid syndrome? Bermejo N, Martín Aguilera C, Bañas H, Arcos MJ, Ibañez F, Salgado R, et al 2014
Relevance of parallel use of galactomanann and betaglucan assay in the diagnosis and follow up of fungal infection Bergua Burgues JM, Siguenza R, Pazos C, Fernandez-Leyva H, Ibañez F, Prieto J, et al 2014
Clinical experience of bosutinib under copasionate use program in chronic myeloid leukemia patients with resitance or intolerance to IMATINIB, DASATINIB and NILOTINIB García-Gutiérrez V, Maestro B, Cervantes F, López Lorenzo JL, Martín Mateos ML, Ávarez A, et al 2014